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Encapsulation of amphotericin B in tuftsin-bearing liposomes greatly increased its efficacy in treatment of human aspergillosis in mice. Also, the 
drug efficacy was significantly increased by pretreating the animals with drug-free tuftsin-bearing liposomes. These results demonstrate that 
macrophage activation can considerably enhance the therapeutic efficacy of antifungal drugs, like amphotericin B. 
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1. INTRODUCTION 
Tuftsin is a natural killer activator of macrophages/ 
monocytes [l] which can easily be grafted onto the sur- 
face of liposomes [2] by attachment of a fatty acyl chain 
through an ethylenediamine spacer arm (Thr-Lys-Pro- 
Arg-NH-(CH,)2-NH-COC,5H3,) to its C-terminus. The 
tuftsin-bearing liposomes (Tuft-Lip) thus formed have 
been shown to be quite effective in activating the host’s 
macrophages [3] and also in increasing non-specific re- 
sistance against parasitic infections [4,5]. 
Lip as amphotericin B (Amp B) vehicles in the treat- 
ment of experimental aspergillosis, as these liposomes, 
besides reducing drug toxicity [7-lo], are also expected 
to activate the host’s macrophages due to the presence 
of the tuftsin on their surface [3]. 
2. MATERIALS AND METHODS 
2.1. Maferials 
Elimination of fungi from the tissues of normal 
healthy subjects is often associated with stimulation of 
cell-mediated immune defences which, for antifungal 
activity, essentially involve activation of mononuclear 
phagocytes by sensitized T cells [6]. The main function 
of these T cells in this case is to release lymphokines 
which in turn arm the macrophages to exhibit the fung- 
istatic or fungicidal activity [6]. In the case of immune 
compromised individuals, however, these mechanisms 
do not operate optimally due to impaired cellular im- 
munity [6]. Since these individuals are the main target 
of systemic fungal infections, treatment of such patients 
with antifungal drugs along with some agent which can 
provoke macrophages/monocytes for their normal 
function should afford obvious advantages over con- 
ventional chemotherapy. Keeping this in view, we con- 
sidered it of interest to evaluate the usefulness of Tuft- 
All the reagents used in the study were of the highest purity availa- 
ble. Cholesterol was bought from Centron Research Laboratory, 
Bombay, and used after crystallizing it three times from methanol. Egg 
phosphatidylcholine (egg PC) was isolated and purified according to 
the published procedure [l 11. Tuftsin modified at the C-terminus was 
prepared as described earlier [2]. Amp B was purchased from Sigma 
Chemical Co. 
2.2. Liposomes 
Liposomes were prepared from egg PC (49 pmol) and cholesterol 
(21 pmol) with or without modified tuftsin (778% by PC weight). All 
the ingredients, along with Amp B (1.0 mg), were dissolved in a 
round-bottomed flask in a minimum volume of chloroform/methanol 
(1: 1, v/v). The solvents were carefully removed under reduced pressure 
so that a thin lipid film formed on the wall of the flask. Final traces 
of the solvent were removed by leaving the flask in vacua overnight 
at 4°C. The dried lipid film was hydrated with 2.0 ml of 150 mM sterile 
saline under vigorous stirring for 1 h in a bath-type sonicator under 
N, atmosphere. The sonicated preparation was dialysed against saline 
for 24 h at 4°C in dark, and then centrifuged at 10,000 x g for 1 h at 
4°C to remove traces of undispersed lipids, The supernatant was 
analysed for both Amp B and tuftsin. 
Correspondence address: CM. Gupta, Institute of Microbial Technol- 
ogy, PO Box 1304, Sector 39-A, Chandigarh 160014, India. Fax: (91) 
(172) 44252. 
2.3. Estimation of Amp B and tuflsin 
The amount of liposome-intercalated Amp B was determined by 
measuring its absorbance at 405 nm. The intercalation efficiencies of 
Amp B in tuftsin-bearing and tuftsin-free liposomes were about 95% 
and 85%. respectively. 
*Present address: Division of Gynecologic Oncology, Roswell Park 
Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263, USA. 
The amount of tuftsin incorporated into hposomes was estimated 
as described earlier [2]. The incorporation efficiency was found to be 
about 98%. 
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2.4. Animals 
Male Balb/C mice weighing 18 ? 2 g were used in the study. The 
animals were given a pellet diet (Hindustan Lever Ltd.) and water ad 
libitum. 
2.5. Infection 
Aspergillusfumigatus (strain VP,,,) originally isolated from an as- 
pergillosis patient at V.P. Chest Institute, New Delhi, was maintained 
in vitro and also in animals. The animals were given a known number 
of spores intravenously 24 h prior to the drug treatment. For prophy- 
lactic studies, the infection was given after treating the animals with 
drug-free Tuft-Lip. 
2.6. Treatment 
Two sets of experiments were carried out under this study. In the 
first set, the efficacy of the various drug formulations was determined 
against the A. Jumigatus infections by measuring both the fungal load 
(CFU) in various organs and survival time of the animals. In the 
second set, the effect of tuftsin-mediated macrophage activation on the 
therapeutic efficacy of Amp B was analysed. In this case, the antifun- 
gal activity of Amp B was evaluated in the animals that were treated 
with Tuft-Lip prior to infection. 
2.6.1. First set 
The infected animals were divided into 5 groups, and then treated 
by being given as follows: Group I, normal saline; Group II, drug-free 
Tuft-Lip; Group III, drug- free, Tuft-free liposomes; Group IV, Tuft- 
free Lip-Amp B; Group V, Tuft-Lip-Amp B. 
2.62. Second set 
The animals were first divided into two groups. The first group was 
pretreated for 3 consecutive days with Tuft-Lip (50 pg Tuft/animal/ 
day) on day l-3 prior to infection, while the second group was left 
untreated. Each group, after beinig infected with A. fumigutus 
(- 1.8 x 10’ spores/animal) was further divided into 3 groups; thus the 
animals were divided into a total of six groups. Group I, pretreated 
animals given no Amp B (PT(+),DT(-)); Group II, pretreated animals 
given Lip-Amp (PT(+),Lip-Amp B)); Group III, pretreated animals 
given Tuft-Lip-Amp B (PT(+),Tuft-Lip-Amp B)); Group IV, un- 
treated animals given no drug (PT(-),DT(-)); Group V, untreated 
animals given Lip-Amp B (PT(-),Lip-Amp B)); Group VI, untreated 
animals given Tuft-Lip-Amp B (PT(-), Tuft-Lip-Amp B)). 
For CFU determination, 3 animals were taken out from each group 
of all the three sets. The animals were sacrificed and livers, lungs, 
kidneys and spleens were dissected out aseptically. The organs were 
minced in normal saline (5 ml) and 200~1 of this suspension was plated 
on rich media, and the plates were incubated for 48 h at 37°C. The 
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Table I 
Effect of Lip-Amp B on A. fumigarus infections in Balb/c mice 
Formulation Survival on day 7 post-treatment 
Exp. I Exp. II Exp. III Exp. IV 
Saline o/4 o/5 O/IO o/14 
Free drug o/5 O/IO 
Empty Liposome o/4 
Empty Tuft-Lip o/4 
Lip-Amp B 3/8 3/10 9125 4/l 1 
Tuft-Lip-Amp B 6/8 11/15 19125 9113 
Drug dose, 0.5 mg/kg (single, i.v.); challenge dose, - 1.8 x 10’ spores/ 
animal. 
colonies were counted and the fungal load calculated by multiplying 
with the dilution factor. 
3. RESULTS AND DISCUSSION 
Balb/c mice infected with A. fumigutus (- 1.8 x 10’ 
spores/animal) were treated with various doses (single, 
intravenous) of Amp B encapsulated in egg PC/cholest- 
erol liposomes. No significant antifungal effects were 
observed when the administered dose of Amp B was 
< 0.5 mg/kg, but at a dose of 0.5 mg/kg, at least 35% 
of the infected animals survived after the treatment. 
This dose was therefore selected for comparing the anti- 
fungal effects of Lip-Amp B with Tuft-Lip-Amp B. 
Table I shows that the % survival of the infected animals 
was considerably increased (70&75%) by treating the 
animals with Tuft-Lip-Amp B. In addition, the animals 
that had survived by day 7 after the Tuft-Lip-Amp B 
treatment were virtually free of fungal infection as com- 
pared to those treated with Lip-Amp B (Table II). These 
results demonstrate that the efficacy of Lip-Amp B 
against A. fumigatus infection is considerably increased 
by grafting tuftsin onto the liposomes surface. 
Table II 
Fungal load in animals that survived infection after treatment with liposomised Amp B 
Organ Fungal load (CFU) 
Exp. I Exp. II Exp. III Exp. IV 
Animals that survived from the Lip-Amp B-treated group 
Liver 187 + 88 307 * 75 258 ? 38 192 f 21 
Lung 625 ? 0 657 + 50 508 f 52 692 f 63 
Kidney 625 ? 176 533 f 74 475 f 25 483 + 16 
Spleen 2,312 + 618 1,282 f 122 1,525 f 44 1,785 + 194 
Animals that survived from the Tuft-Lip-Amp B-treated group 
Liver 0 0 0 0 
Lung 0 0 0 0 
Kidney 0 50* 25+ 0 
Spleen 0 0 25* 0 
The fungal load was determined on day 7 post-treatment. Values are means of 3 animals f S.D. *Fungal load in one animal. 
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Table I11 
Effect of Tuft-Lip pretreatment on the efficacy of Lip-Amp B against fungal infections 
Treatment Survival on day 7 Fungal load (CFU) 24 h after drug treatment 
post-drug treatment 
Liver Lung Kidney Spleen 
PT(-),DT(-) o/7 71,042 * 3,442 53,542 + 2,602 19,166 f 2,194 39,170 f 1,301 
PT(-),Lip-Amp B 4112 23,125 + 1,654 13,333 + 954 7,708 t 360 17,916 + 954 
PT(-),Tuft-Lip-Amp B 9112 9,167 + 954 2,291 f 360 5,208 ? 360 16,875 ? 1,275 
PT(+),DT(-) l/7 29,583 ? 2,525 20,833 f 2,009 14,375 ? 1,875 33,958 * 954 
PT(+),Lip-Amp B 617 2,916 f 721 1,875 f 625 4,792 f 721 13,541 f 954 
PT(+),Tuft-Lip-Amp B 617 2,708 f 360 1,041 2 360 2,500 + 625 12,708 2 360 
Drug dose, 0.5 mg/kg (single, iv.); challenge dose, - 1.8 x IO’ spores/animal. PT, pretreatment; DT, drug treatment. Values are means of 3 
animals ? SD. 
Monocyteslmacrophages are the key line of host de- 
fence against pathogenic fungi [6]. As tuftsin is known 
to increase the killer activity of these cells [I], the ob- 
served increase in the therapeutic efficacy of Amp B 
after its encapsulation in Tuft-Lip may partly be attri- 
buted to macrophage activation. To further examine the 
validity of this conclusion, we determined the effects of 
Lip-Amp B on the initial fungal load, which was meas- 
ured 24 h after the drug treatment, and the % survival 
(on day 7 post-drug treatment) in mice that were treated 
with Tuft-Lip prior to the A. fumigatus infection. The 
data shown in Table III indicate that the Tuft-Lip pre- 
treatment not only reduced the initial fungal load but 
also increased the % survival in Lip-Amp-treated ani- 
mals. In the pretreated groups, both Lip-Amp B and 
Tuft-Lip-Amp B were equally effective, confirming that 
macrophage activation does increase the therapeutic ef- 
ficacy of the antifungal drug, Amp B. These results thus 
strongly indicate that the chemotherapeutic efficacy of 
some antifungal drugs can be markedly increased by 
administering them along with macrophage activators 
in liposomes. 
Amp B is a potent antifungal drug but its therapeutic 
use is limited due to its high toxicity. The toxicity has, 
however, been shown to considerably decrease without 
affecting the drug’s efficacy by encapsulating this drug 
in liposomes [7-lo], thus rendering Amp B suitable for 
use in the treatment of fungal infections. The present 
study further increases the scope of liposomised Amp 
B formulations in the treatment of fungal infections by 
demonstrating a significant improvement in the Lip- 
Amp B efficacy against experimental aspergillosis after 
grafting tuftsin onto the surface of liposomes. This 
modification of the Lip-Amp B surface, however, did 
not affect the drug toxicity, as we observed almost iden- 
tical LD,, values (7-8 mg/kg) for both Lip-Amp B and 
Tuft-Lip-Amp B. 
In conclusion, this study shows that the Tuft-Lip- 
Amp B formulation is considerably better than the Lip- 
Amp B preparation in the treatment of systemic fungal 
infections due to its higher efficacy and comparable 
toxicity. In addition, it suggests that administration of 
macrophage activators/immunomodulators along with 
Amp B in liposomes should greatly improve the efficacy 
of fungal chemotherapy. 
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